Dermatological Drugs Market Worth $31.97bn In 2021

 
 
vg
vg
 
Spread the Word
Listed Under

Tags:
Dermatology
Dermatitis
Psoriasis

Industry:
Business

Location:
London City - London, Greater - England

Subject:
Reports

LONDON - Nov. 7, 2017 - PRLog -- Visiongain's new report Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma indicates that the dermatological drugs market will see $31.97bn in spending in 2021.

The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.

Nasreen Uddin, a pharmaceutical industry analyst for visiongain, said: "The Dermatological drugs market has seen fast growth over the years. This is due partly to the high growth potential of biological treatments for psoriasis and companies exploring novel mechanisms of action with target specific treatment. The development of new antibacterial drugs to address the problems of ageing population and drug-resistant strains of bacteria will also contribute to the overall market growth.

While the US remains the largest national market for dermatological drugs, higher growth is expected in emerging markets, with China becoming the 2nd largest national market towards the end of the forecast. This will be driven by increasing access to healthcare, economic growth and rising prevalence of skin disorders. The industry will continue to witness increased consolidation and partnering between drug companies to provide for better research and development and address unmet medical needs"

The 296-page report contains 111 tables and 92 figures that add visual analysis in order to explain the developing trends within the Dermatological Drugs Market.

Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the dermatological drugs market and its leading submarkets: Psoriasis, Skin Infection, Acne, Dermatitis.

The 296-page report offers market forecasts for the leading drugs of the leading submarkets, including Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, and others.

This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval. Visiongain interviewed two companies

Our work discusses the leading companies in the dermatological drugs market. Our study also discusses SWOT and Porter's Five Force analysis that influence the dermatological drugs market. Moreover, this report provides transcripts of two interviews conducted by visiongain with experts in the dermatological drugs market.

The report Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma report will be of value to anyone who wants to better understand the dermatological drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the dermatological drugs market.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com (mailto:sara.peerun@visiongainglobal.com) or call her on +44 (0) 207 336 6100.

About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Contact
Sara Peerun
***@visiongain.com
End
Email:***@visiongain.com Email Verified
Tags:Dermatology, Dermatitis, Psoriasis
Industry:Business
Location:London City - London, Greater - England
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Visiongain PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share